An ex vivo model for anti-angiogenic drug testing on intact microvascular networks.
New models of angiogenesis that mimic the complexity of real microvascular networks are needed. Recently, our laboratory demonstrated that cultured rat mesentery tissues contain viable microvascular networks and could be used to probe pericyte-endothelial cell interactions. The objective of this stu...
Main Authors: | , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2015-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC4350846?pdf=render |
id |
doaj-b73bab591a3b48fca43467d3cb17bf3a |
---|---|
record_format |
Article |
spelling |
doaj-b73bab591a3b48fca43467d3cb17bf3a2020-11-25T01:31:39ZengPublic Library of Science (PLoS)PLoS ONE1932-62032015-01-01103e011922710.1371/journal.pone.0119227An ex vivo model for anti-angiogenic drug testing on intact microvascular networks.Mohammad S AzimiLeann MyersMichelle LaceyScott A StewartQirong ShiPrasad V KatakamDebasis MondalWalter L MurfeeNew models of angiogenesis that mimic the complexity of real microvascular networks are needed. Recently, our laboratory demonstrated that cultured rat mesentery tissues contain viable microvascular networks and could be used to probe pericyte-endothelial cell interactions. The objective of this study was to demonstrate the efficacy of the rat mesentery culture model for anti-angiogenic drug testing by time-lapse quantification of network growth. Mesenteric windows were harvested from adult rats, secured in place with an insert, and cultured for 3 days according to 3 experimental groups: 1) 10% serum (angiogenesis control), 2) 10% serum + sunitinib (SU11248), and 3) 10% serum + bevacizumab. Labeling with FITC conjugated BSI-lectin on Day 0 and 3 identified endothelial cells along blood and lymphatic microvascular networks. Comparison between day 0 (before) and 3 (after) in networks stimulated by 10% serum demonstrated a dramatic increase in vascular density and capillary sprouting. Growing networks contained proliferating endothelial cells and NG2+ vascular pericytes. Media supplementation with sunitinib (SU11248) or bevacizumab both inhibited the network angiogenic responses. The comparison of the same networks before and after treatment enabled the identification of tissue specific responses. Our results establish, for the first time, the ability to evaluate an anti-angiogenic drug based on time-lapse imaging on an intact microvascular network in an ex vivo scenario.http://europepmc.org/articles/PMC4350846?pdf=render |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Mohammad S Azimi Leann Myers Michelle Lacey Scott A Stewart Qirong Shi Prasad V Katakam Debasis Mondal Walter L Murfee |
spellingShingle |
Mohammad S Azimi Leann Myers Michelle Lacey Scott A Stewart Qirong Shi Prasad V Katakam Debasis Mondal Walter L Murfee An ex vivo model for anti-angiogenic drug testing on intact microvascular networks. PLoS ONE |
author_facet |
Mohammad S Azimi Leann Myers Michelle Lacey Scott A Stewart Qirong Shi Prasad V Katakam Debasis Mondal Walter L Murfee |
author_sort |
Mohammad S Azimi |
title |
An ex vivo model for anti-angiogenic drug testing on intact microvascular networks. |
title_short |
An ex vivo model for anti-angiogenic drug testing on intact microvascular networks. |
title_full |
An ex vivo model for anti-angiogenic drug testing on intact microvascular networks. |
title_fullStr |
An ex vivo model for anti-angiogenic drug testing on intact microvascular networks. |
title_full_unstemmed |
An ex vivo model for anti-angiogenic drug testing on intact microvascular networks. |
title_sort |
ex vivo model for anti-angiogenic drug testing on intact microvascular networks. |
publisher |
Public Library of Science (PLoS) |
series |
PLoS ONE |
issn |
1932-6203 |
publishDate |
2015-01-01 |
description |
New models of angiogenesis that mimic the complexity of real microvascular networks are needed. Recently, our laboratory demonstrated that cultured rat mesentery tissues contain viable microvascular networks and could be used to probe pericyte-endothelial cell interactions. The objective of this study was to demonstrate the efficacy of the rat mesentery culture model for anti-angiogenic drug testing by time-lapse quantification of network growth. Mesenteric windows were harvested from adult rats, secured in place with an insert, and cultured for 3 days according to 3 experimental groups: 1) 10% serum (angiogenesis control), 2) 10% serum + sunitinib (SU11248), and 3) 10% serum + bevacizumab. Labeling with FITC conjugated BSI-lectin on Day 0 and 3 identified endothelial cells along blood and lymphatic microvascular networks. Comparison between day 0 (before) and 3 (after) in networks stimulated by 10% serum demonstrated a dramatic increase in vascular density and capillary sprouting. Growing networks contained proliferating endothelial cells and NG2+ vascular pericytes. Media supplementation with sunitinib (SU11248) or bevacizumab both inhibited the network angiogenic responses. The comparison of the same networks before and after treatment enabled the identification of tissue specific responses. Our results establish, for the first time, the ability to evaluate an anti-angiogenic drug based on time-lapse imaging on an intact microvascular network in an ex vivo scenario. |
url |
http://europepmc.org/articles/PMC4350846?pdf=render |
work_keys_str_mv |
AT mohammadsazimi anexvivomodelforantiangiogenicdrugtestingonintactmicrovascularnetworks AT leannmyers anexvivomodelforantiangiogenicdrugtestingonintactmicrovascularnetworks AT michellelacey anexvivomodelforantiangiogenicdrugtestingonintactmicrovascularnetworks AT scottastewart anexvivomodelforantiangiogenicdrugtestingonintactmicrovascularnetworks AT qirongshi anexvivomodelforantiangiogenicdrugtestingonintactmicrovascularnetworks AT prasadvkatakam anexvivomodelforantiangiogenicdrugtestingonintactmicrovascularnetworks AT debasismondal anexvivomodelforantiangiogenicdrugtestingonintactmicrovascularnetworks AT walterlmurfee anexvivomodelforantiangiogenicdrugtestingonintactmicrovascularnetworks AT mohammadsazimi exvivomodelforantiangiogenicdrugtestingonintactmicrovascularnetworks AT leannmyers exvivomodelforantiangiogenicdrugtestingonintactmicrovascularnetworks AT michellelacey exvivomodelforantiangiogenicdrugtestingonintactmicrovascularnetworks AT scottastewart exvivomodelforantiangiogenicdrugtestingonintactmicrovascularnetworks AT qirongshi exvivomodelforantiangiogenicdrugtestingonintactmicrovascularnetworks AT prasadvkatakam exvivomodelforantiangiogenicdrugtestingonintactmicrovascularnetworks AT debasismondal exvivomodelforantiangiogenicdrugtestingonintactmicrovascularnetworks AT walterlmurfee exvivomodelforantiangiogenicdrugtestingonintactmicrovascularnetworks |
_version_ |
1725085307443871744 |